Pliant Therapeutics Announces Presentations at the International Liver Congress(TM) 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

SOUTH SAN FRANCISCO, Calif., June 24, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the presentation of two scientific posters at the International Liver Congress(TM) (ILC) 2022 of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022, in London, United Kingdom.

The post Pliant Therapeutics Announces Presentations at the International Liver Congress(TM) 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial appeared first on Bio Tech Winners.

Read MoreBio Tech Winners